FDA OKs additional indication for SPECT agent AdreView

03/24/2013 | AuntMinnie.com (free registration)

The FDA has allowed the use of GE Healthcare's SPECT imaging agent AdreView, also known as iobenguane I-123, in the evaluation of myocardial sympathetic innervation in patients with New York Heart Association class II or III heart failure and left-ventricular ejection fraction at or lower than 35%. The company said the agent has the potential to detect the likelihood that patients' heart failure will advance.

View Full Article in:

AuntMinnie.com (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA